These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 29724381

  • 1. Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler.
    Kappeler D, Sommerer K, Kietzig C, Huber B, Woodward J, Lomax M, Dalvi P.
    Respir Med; 2018 May; 138():107-114. PubMed ID: 29724381
    [Abstract] [Full Text] [Related]

  • 2. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
    Van Holsbeke C, De Backer J, Vos W, Marshall J.
    Ther Adv Respir Dis; 2018 May; 12():1753466618760948. PubMed ID: 29499614
    [Abstract] [Full Text] [Related]

  • 3. An innovative corticosteroid/long-acting β2-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma.
    Usmani O, Roche N, Marshall J, Danagher H, Price D.
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler® Device in Healthy Subjects, Asthmatic Patients, and COPD Patients.
    Virchow JC, Poli G, Herpich C, Kietzig C, Ehlich H, Braeutigam D, Sommerer K, Häussermann S, Mariotti F.
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
    Taylor G, Warren S, Dwivedi S, Sommerville M, Mello L, Orevillo C, Maes A, Martin UJ, Usmani OS.
    Eur J Pharm Sci; 2018 Jan 01; 111():450-457. PubMed ID: 29055732
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).
    Malmberg LP, Everard ML, Haikarainen J, Lähelmä S.
    J Aerosol Med Pulm Drug Deliv; 2014 Oct 01; 27(5):329-40. PubMed ID: 24978441
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy Volunteers.
    Dissanayake S, Mundin G, Woodward J, Lomax M, Dalvi P.
    J Aerosol Med Pulm Drug Deliv; 2023 Apr 01; 36(2):65-75. PubMed ID: 36796001
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 01; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.
    Papi A, Price D, Sastre J, Kaiser K, Lomax M, McIver T, Dissanayake S.
    Respir Med; 2015 Feb 01; 109(2):208-17. PubMed ID: 25575940
    [Abstract] [Full Text] [Related]

  • 13. Plume Characteristics of Two HFA-Driven Inhaled Corticosteroid/Long-Acting Beta2-Agonist Combination Pressurized Metered-Dose Inhalers.
    Johal B, Murphy S, Tuohy J, Marshall J.
    Adv Ther; 2015 Jun 01; 32(6):567-79. PubMed ID: 26100350
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P, DePetrillo P, Reisner C, St Rose E, Dorinsky P.
    Pulm Pharmacol Ther; 2018 Jun 01; 50():11-18. PubMed ID: 29544728
    [Abstract] [Full Text] [Related]

  • 16. Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate.
    Shrewsbury SB, Armer TA, Newman SP, Pitcairn G.
    Int J Pharm; 2008 May 22; 356(1-2):137-43. PubMed ID: 18289809
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
    Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K.
    Respir Med; 2013 Feb 22; 107(2):180-95. PubMed ID: 23273405
    [Abstract] [Full Text] [Related]

  • 18. Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects.
    Israel S, Kumar A, DeAngelis K, Aurivillius M, Dorinsky P, Roche N, Usmani OS.
    Eur J Pharm Sci; 2020 Oct 01; 153():105472. PubMed ID: 32682074
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI.
    Murphy KR, Dhand R, Trudo F, Uryniak T, Aggarwal A, Eckerwall G.
    Respir Med; 2015 Feb 01; 109(2):170-9. PubMed ID: 25596138
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.